Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Immunotherapy with programmed death receptor-1 (PD-1) inhibitors, as a single agent or in combination with chemotherapy, is the standard first-line treatment for recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC). Unfortunately, there is no established second-line treatment for the many patients who fail immunotherapy. Cetuximab is the only targeted therapy approved in HNSCC but historically has a low response rate of 13%.
Objectives: We hypothesize that cetuximab monotherapy following an immune checkpoint inhibitor (ICI) will lead to increased efficacy due to a potential synergistic effect on the antitumor immune response, as a result of activation effects of both treatments on innate and adaptative immune responses. To the authors' knowledge, this is the only ongoing prospective clinical study that evaluates the combination of cetuximab and ICIs administered sequentially.
Methods And Analysis: In this non-randomized, open-label, phase II trial, 30 patients with R/M HNSCC who have previously failed or could not tolerate a PD-1 inhibitor as a single agent or in combination with chemotherapy will subsequently be treated with cetuximab monotherapy. Outcomes of interest include overall response rate, duration of response, progression-free survival, overall survival, and treatment toxicity, as well as treatment outcome measured by a patient-reported outcome questionnaire. Saliva and blood will be collected for correlative studies to investigate the immune response status at the end of therapy with an ICI and the effect of cetuximab on the antitumor immune response. The results will be correlated with the response to cetuximab and the time window between the last administration of an ICI and the loading dose of cetuximab. The clinical study is actively recruiting.
Ethics: This study was approved by the Wake Forest Comprehensive Cancer Center Institutional Review Board: IRB00065239.
Clinical Trial Registration: This study is registered on ClinicalTrials.gov: NCT04375384.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10799583 | PMC |
| http://dx.doi.org/10.1177/17588359231217959 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Oral Oncol
September 2025
Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Despite overexpression of EGFR in head/neck squamous cell carcinoma (HNSCC), cetuximab monotherapy has limited benefit. Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor with activity against FGFRs1-4, involved in resistance to EGFR inhibition. We evaluated lenvatinib in combination with cetuximab in recurrent/metastatic (R/M) HNSCC.
View Article and Find Full Text PDFAvelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial.
Br J Dermatol
July 2025
Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany.
Background: In cutaneous squamous cell carcinoma (cSCC), PD-1 and EGFR inhibitors are effective in a considerable proportion of patients. However, there is an unmet medical need for patients with perianogenital cSCC or cSCC refractory to PD-1 therapy.
Patients And Methods: This multicentre phase-2 trial enrolled patients with advanced cSCC (prior systemic therapy allowed) to receive the PD-L1 inhibitor avelumab (10 mg/kg q2w) plus the EGFR inhibitor cetuximab (500 mg/m2 q2w) for up to 1 year.
Targeting KRAS in colorectal cancer (Review).
Mol Clin Oncol
September 2025
Clinical Trials Center, Luanzhou People's Hospital, Tangshan, Hebei 063700, P.R. China.
RAS genes play crucial roles in regulating important biological processes such as cell growth, differentiation, and apoptosis in normal cells. When RAS genes undergo mutations or abnormal expression, they can become oncogenic drivers, and the oncogenic mechanism of KRAS mutations which drive cancer progression is highly complex. Colorectal cancer carrying KRAS mutation genes often exhibits poor prognosis.
View Article and Find Full Text PDFColorectal cancer (CRC) remains the second-leading cause of cancer-associated deaths, indicating an urgent need for improved therapeutic options. We previously generated antibody-drug conjugates (ADCs) targeting the cancer stem-like cell marker leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). However, tumor relapse due to LGR5 downregulation and suboptimal payload selection warranted strategies to improve ADC efficacy.
View Article and Find Full Text PDFPhase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors.
Clin Cancer Res
July 2025
Dana-Farber Cancer Institute, Boston, MA, United States.
Purpose: To evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ficerafusp alfa (BCA101), a first-in-class bifunctional protein targeting epidermal growth factor receptor (EGFR) and TGF-β, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
Patients And Methods: At escalating doses in a parallel 3+3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa monotherapy (64-1500 mg) or in combination (240-1500 mg) with pembrolizumab (200 mg intravenously every 3 weeks). The primary objective was to determine safety/tolerability.